Perspective Therapeutics (CATX) said Monday the first patient was dosed in a new cohort of its phase 1/2a trial evaluating the safety of targeted alpha-particle therapy [212Pb]VMT01 in patients with histologically confirmed melanoma and positive melanocortin 1 receptor imaging scans.
Patients in the new cohort are receiving the therapy in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb (BMY) as Opdivo, compared to earlier cohorts where the patients received it as monotherapy, the company said.
The data from this part of the study will enable the company to further understand "how lower-dose radiopharmaceuticals can be optimized in combination with immunotherapies," Perspective CEO Thijs Spoor said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。